Real-life use of tocilizumab with or without corticosteroid in hospitalized patients with moderate-to-severe COVID-19 pneumonia: A retrospective cohort study.
Gianluca RussoAngelo SoliminiPaola ZuccalàMaria Antonella ZingaropoliAnna CarraroPatrizia PasculliValentina PerriRaffaella MaroccoBlerta KertushaCosmo Del BorgoEmanuela Del GiudiceLaura FondacoTiziana TieghiClaudia D'AgostinoAlessandra OlivaVincenzo VulloMaria Rosa CiardiClaudio Maria MastroianniMiriam LichtnerPublished in: PloS one (2021)
Although contrasting results from randomized clinical trials to date, in our experience tocilizumab was a safe and efficacious therapeutic option for patients with moderate-to-severe COVID-19 pneumonia. Its efficacy was improved by the concomitant administration of corticosteroids in patients affected by severe-COVID-19 pneumonia at baseline.
Keyphrases
- coronavirus disease
- sars cov
- rheumatoid arthritis
- end stage renal disease
- early onset
- ejection fraction
- chronic kidney disease
- newly diagnosed
- high intensity
- juvenile idiopathic arthritis
- prognostic factors
- rheumatoid arthritis patients
- peritoneal dialysis
- community acquired pneumonia
- drug induced
- systemic lupus erythematosus
- patient reported outcomes
- extracorporeal membrane oxygenation